Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants
Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants
复制标题
DOI：
10.1542/peds.2005-1543
复制
发表时间：
2006-02-01
期刊：
影响因子：
8
通讯作者：
Phelps, DL
中科院分区：
文献类型：
--
作者：
Guillet, R;Stoll, BJ;Phelps, DL
OBJECTIVE.我们试图确定在出生体重为401 - 1500 g的婴儿中使用组胺-2受体（H2）阻滞剂与坏死性小肠结肠炎（NEC）的发病率之间是否存在关联。从1998年9月至2001年12月，从国家儿童健康和人类发展研究所新生儿研究网络极低出生体重（401 - 1500克）登记的数据进行了分析。NEC（贝尔II期或更高）的诊断和前期H2受体阻滞剂治疗之间的关系进行了确定，通过使用病例对照方法。进行条件Logistic回归分析，控制性别、出生地点（外生与先天）、5分钟时Apgar评分< 7和产后类固醇。在存活至少12小时的11072名婴儿中，787名（7.1%）发生NEC（401 - 750 g婴儿的11.5%，751 - 1000 g婴儿的9.1%，1001 - 1250 g婴儿的6.0%，1251 - 1500 g婴儿的3.9%）。既往使用H2受体阻滞剂与NEC发生率增加相关（P
OBJECTIVE. We sought to determine if an association exists between the use of histamine-2 receptor (H2) blockers and the incidence of necrotizing enterocolitis (NEC) in infants of 401 to 1500 g in birth weight.STUDY DESIGN. Data from the National Institute of Child Health and Human Development Neonatal Research Network very low birth weight (401 - 1500 g) registry from September 1998 to December 2001 were analyzed. The relation between the diagnosis of NEC (Bell stage II or greater) and antecedent H2-blocker treatment was determined by using case-control methodology. Conditional logistic regression was implemented, controlling for gender, site of birth (outborn versus inborn), Apgar score of < 7 at 5 minutes, and postnatal steroids.RESULTS. Of 11 072 infants who survived for at least 12 hours, 787 (7.1%) developed NEC (11.5% of infants 401 - 750 g, 9.1% of infants 751 - 1000 g, 6.0% of infants 1001 - 1250 g, and 3.9% of infants 1251 - 1500 g). Antecedent H2-blocker use was associated with an increased incidence of NEC (P